Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Calendar
  • Grants
  • About Akademiliv

New studies support blood test for early detection of Alzheimer’s disease

13 January, 2021 Leave a Comment

NEW STUDIES. In three recent publications in Molecular Psychiatry, Brain and JAMA Neurology researchers from the University of Gothenburg provide convincing evidence that an in-house developed blood test for Alzheimer’s disease can detect the disease early and track its course, which has major implications for a potential use in clinical practice and treatment trials. 

Michael Schöll

“This is an extremely dynamic research field right now, thanks to the technological development and seminal scientific progress in the past years. The dream scenario is to have a blood test for the early detection and screening of Alzheimer’s disease up and running. That would give significantly more people in the world access to testing and future treatments”, says Michael Schöll, associate professor and one of the senior authors. 

After decades of research, we now know that Alzheimer’s disease-related memory problems are just the tip of the iceberg of underlying degenerative processes in the brain that have been silently developing over years or even decades. 

These processes result from abnormal aggregation of amyloid and tau proteins in the brain, with these aggregates being the defining pathological features of Alzheimer’s disease. Until recently, it was only possible to detect these protein aggregates in the brains of deceased patients at autopsy. 

Recent research advances, however, have enabled the accurate detection of amyloid and tau pathology in the brain with imaging methods and in the cerebrospinal fluid of living individuals. These current so-called biomarker methods are either expensive, invasive, or only available at specialized centers; thus, only a fraction of patients suffering from the disease currently benefit from these advances. 

Solid research base 

An accessible, affordable, and minimally invasive biomarker for Alzheimer’s disease would revolutionize care of patients worldwide, as well as boost the development of novel drugs for this presently still incurable disease.     

In 2020, researchers at Sahlgrenska Academy, University of Gothenburg, have discovered such a biomarker: a cheap blood test capable to detect the presence of phosphorylated tau protein (p-tau181), a principal, defining hallmark of Alzheimer’s disease. Three recent scientific articles from the same study group now focus on the diagnostic performance of this blood marker and how it changes over time during healthy aging and during disease. 

Thomas Karikari

The authors demonstrated great potential for the blood test to predict and monitor Alzheimer’s disease progression in an unprecedently large study comprising more than 1100 subjects from the Alzheimer’s Disease Neuroimage Initiative (ADNI), followed up over several years. 

First authors are Thomas Karikari (the article in Molecular Psychiatry) and Alexis Moscoso (Brain and JAMA Neurology). 

Alexis Moscoso

“The recent development of blood tests sensitive to Alzheimer’s disease pathology is likely to provide a solution and has the potential to significantly change the way this disease can be managed in the near future”, Moscoso says. 

In the publication in Brain the researchers analyzed participants’ blood samples acquired at different ages to construct the temporal trajectory of p-tau181 levels in blood across the long course of Alzheimer’s disease. 

Importantly, they found that the novel blood test could detect abnormalities in p-tau181 levels several years before the onset of memory loss, suggesting enormous potential for early disease detection. 

Major step forward 

This potential was further confirmed in another publication in Molecular Psychiatry, with first author Thomas Karikari, in which the investigators demonstrated the high clinical utility of p-tau181 in blood for predicting future Alzheimer’s disease dementia, even among individuals who had not experienced any memory impairment in the moment of the blood test. 

Finally, in the third and most recent publication in JAMA Neurology, the scientists demonstrated that annual increases of p-tau181 in blood were strongly coupled to the loss of nerve cells in Alzheimer’s disease as well as to cognitive decline, suggesting not only potential for prediction but also for monitoring and identifying rapidly progressive forms of the disease in an affordable yet effective way. Professor Henrik Zetterberg: 

Henrik Zetterberg

“Our findings have clear and novel implications for the use of these tests, both as diagnostic tools, but also as outcome measures in clinical trials, as we showed that the levels of phosphorylated p-tau181 and Neurofilament light, NfL, in standard blood samples, are reliable biomarkers for Alzheimer’s disease, specifically p-tau181, and for neurodegenerative diseases in general, NfL.” 

Kaj Blennow

Together, these studies represent a crucial step towards the widespread use of biomarkers in clinical routine, making effective blood biomarker testing for Alzheimer’s disease a reality for most clinical settings, including primary care. Professor Kaj Blennow: 

“This is a major step forward showing that blood tests for tau pathology and neurodegeneration have clinical value to track disease progression in patients with Alzheimer’s disease”, he says. 

Titles and links: 

  • Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum, https://doi.org/10.1093/brain/awaa399 
  • Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative, https://doi.org/10.1038/s41380-020-00923-z 
  • Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease, https://doi.org/10.1001/jamaneurol.2020.4986 
  • https://jamanetwork.com/journals/jamaneurology/fullarticle/2774467 

TEXT: MARGARETA GUSTAFSSON KUBISTA

By: Elin Lindström
Tagged With: Alzheimers sjukdom, institutionen för neurovetenskap och fysiologi

Leave a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Add your own events in the Akademiliv Calendar

Webinar: SAGE Research Methods

Forskarsnabben – full autumn program

During 20 minutes over Zoom, the Biomedical Library gives tips on tools and services that can facilitate your research everyday life. Start January 27.
English version further down in the document.

The novel coronavirus – University-wide information on the Staff Portal

Read up-tp-date information regarding how effects of the pandemic are handled at the university.

The entrance doors are locked

Due to new restrictions and decisions, all entrances are locked. For daytime access, use your GU card.

We are building at Medicinareberget

You will now find comprehensive information on construction projects that affect the Sahlgrenska Academy in the Staff Portal.

Lunch menus

Café & restaurang Anatomen

Gastronomen på SU

Lunchen.nu

Lyktan lunchservering

Lustgården på Änggårdsbacken

Café Anne Dahl

More news

Continued stricter regulations at University of Gothenburg

22 January, 2021

COVID-19. The stricter restrictions that currently exist at the University of Gothenburg have been extended until further notice. This means that …  

Karl Swedberg discusses study in NEJM on increasing contractility by stimulation with pharmaceutical agent

20 January, 2021

COMMENTARY. Karl Swedberg, a senior professor and a renown international researcher in heart failure, has written an editorial in the latest …  

SEK 13.6 million for childhood cancer research in Gothenburg

19 January, 2021

GRANTS. In its latest funding round, the Swedish Childhood Cancer Fund awarded a total of SEK 146 million for Swedish research, which is a new …  

Many advantages with double degrees – a well-functioning collaboration enabled her defense of dissertation

19 January, 2021

DOCTORAL EDUCATION. The first doctoral student admitted to doctoral studies at both Sahlgrenska Academy and KU Leuven has now defended her …  

New principle for cancer treatment shows promising effect

18 January, 2021

NEW STUDY. A new type of inhibitor that interferes with mitochondrial function in cancer cells has been developed in a collaboration involving …  

Justin Schneiderman’s new assignment supports management in AI developments

18 January, 2021

AI NYTT. We can use artificial intelligence for many things, including for organizing otherwise unmanageable amounts of data or developing …  

Regarding media attention around exam in the university’s examination halls

18 January, 2021

EXAMINATION. Media is reporting that about 150 students at the University of Gothenburg during the current pandemic will gather today Friday, to …  

Construction information Medicinareberget – Walls for Natrium’s first floor soon in place

18 January, 2021

CONSTRUCTION INFORMATION. Akademiliv provides information on the construction of Natrium on Medicinareberget for the period weeks 51-02 (December …  

Researchers identify a new biomarker for the childhood cancer neuroblastoma

15 January, 2021

NEW STUDY. In collaboration with researchers in the Netherlands and Belgium, researchers at the University of Gothenburg have now shown that …  

Researchers can begin applying to use SCAPIS data from March 17

14 January, 2021

RESEARCH. The launch of unique SCAPIS is approaching. SCAPIS is a bank of data, blood samples and bioimages from 30,000 participants that will be …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström Claessen is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen